Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ValiRx PLC (GB:VAL)
LSE:VAL
Holding GB:VAL?
Track your performance easily
VAL Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1.85p - 15.00p
Previous Close2.8p
Volume1.22M
Average Volume (3M)1.83M
Market Cap
£3.71M
Enterprise Value2.38M
Total Cash (Recent Filing)£1.14M
Total Debt (Recent Filing)£37.71K
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Sep 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding132,348,673
10 Day Avg. Volume828,885
30 Day Avg. Volume1,828,947
Standard Deviation0.47
R-Squared0.06
Alpha-0.00795
Financial Highlights & Ratios
Price to Book (P/B)1150.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ValiRx plc News
PremiumCompany Announcements
ValiRx’s Inaphaea Inks Deal with Xenopat for Cancer Research
PremiumCompany Announcements
ValiRx Subsidiary Strikes US Co-Marketing Deal
PremiumCompany Announcements
ValiRx plc Announces Upcoming Investor EveningPremiumCompany Announcements
ValiRx Subsidiary Inks Deal for Cancer Model Development
PremiumCompany Announcements
ValiRx Subsidiary Inks Deal with BioReperia AB
PremiumCompany Announcements
ValiRx Welcomes New CEO Dr Mark Eccleston
PremiumCompany Announcements
ValiRx plc Announces Strategic Board Appointments
PremiumCompany Announcements
ValiRx Announces New Executive Director AppointmentOptions Prices
Currently, No data available
---
Ownership Overview
91.92% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
8.08% Public Companies and
Individual Investors
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 1.85p and its highest was 15.00p in the past 12 months.
What is ValiRx PLC’s market cap?
Currently, no data Available
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Sep 26, 2024 which is in 6 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Aug 24, 2023. The company reported -0.01p earnings per share for the quarter, missing the consensus estimate of N/A by -0.01p.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 132,348,680 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -0.01p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.82%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
---
ValiRx plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.12%
12-Months-Change
Fundamentals
Return on Equity
-56.06%
Trailing 12-Months
Asset Growth
-21.27%
Trailing 12-Months
Company Description
ValiRx PLC
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in the epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.
---
Technical Analysis
---